Overall survival of patients with relapsed B-cell lymphomas undergoing high dose chemoradiotherapy with either a standard preparative regimen or one containing myeloablative doses of Iodine-131-tositumomab.

Fifty-two patients were treated with I-131-tositumomab (at doses delivering up to 25 Gy to normal organs), etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and autologous stem cell transplantation (upper line). The overall survival is compared to a non-randomized control group of 105 patients transplanted using external beam total body irradiation (TBI 1.5 Gy twice a day for four days), etoposide (60 mg/kg), cyclophosphamide (100 mg/kg) and ASCT (bottom line). Figure reproduced with permission from Press et al.⁴⁵